Vericel Corporation (VCEL)
Vericel Corporation (VCEL) is a biotechnology company specializing in the development and commercialization of autologous cell therapy products for the treatment of sports-related injuries, including cartilage and tendon repair. The company focuses on regenerative medicine technologies aimed at improving patient outcomes in musculoskeletal conditions.
Company News
MediWound reported a 43% quarterly revenue increase to $5.7 million, improved gross margins, and advanced its Phase III EscharEx trial while establishing strategic partnerships with wound care leaders.
Vericel Corporation reported strong financial results for the second quarter of 2024, with record revenue, MACI revenue growth, and significant margin expansion. The company also provided an update on the progress of its NexoBrid launch and raised its full-year profitability guidance.
Vericel Corp's Chief Legal Officer, Sean C. Flynn, has sold $782,700 worth of company stock as part of a prearranged trading plan. The transaction comes amid the company's strong financial performance and positive analyst coverage.
Throughout the last three months, 4 analysts have evaluated Vericel (NASDAQ:VCEL), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferen...
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 44.44% and 0%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?